Results 231 to 240 of about 15,828 (290)

How abciximab might be clinically useful

International Journal of Cardiology, 2016
Platelet aggregation is a crucial feature in coronary artery thrombus formation and is a major causative factor in both acute coronary syndromes (ACS) and reocclusion after percutaneous coronary interventions (PCI). The glycoprotein (GP) IIb/IIIa (αIIbβ3) integrin receptor is the pivotal mediator of platelet aggregation. In late 1990s, the introduction
Coşkun Usta, Nur Tukel Turgut, Aslı Bedel   +2 more
openaire   +4 more sources

Pharmacological Properties of Abciximab [PDF]

Hämostaseologie, 1999
AbstractAbciximab is the first of a new class of therapeutic agents that specifically block the function of the platelet cell adhesion receptor, glycoprotein (GP) IIb/IIIa and the subsequent platelet aggregation that contributes to thrombosis. Abciximab displays high avidity for the GPIIb/IIIa receptor, which results in a prolonged platelet-bound half ...
Mary Ann Mascelli, Marian T. Nakada
openaire   +1 more source

Coronary stenting and use of abciximab

The Lancet, 1998
1claim that “a new standard for prevention of major adverse ischaemic outcomes with percutaneous coronary revascularisation procedures has emerged”, and caution that “the cost effectiveness of abciximab needs to be fully assessed”. A critical issue that they do not address is the outcome of patients requiring emergency coronary-artery bypass graft ...
Wolfgang Mohl, Markus Menges, Hermann Schieffer, Benno Hennen, Martin Zeitz   +4 more
  +8 more sources

Antithrombotic effects of Abciximab

The American Journal of Cardiology, 2000
The observation that platelet-platelet interaction and thrombosis are ultimately regulated by the glycoprotein (GP) IIb/IIIa receptor complex, triggered the development of agents capable of interfering with this platelet receptor complex. Several large clinical trials have demonstrated the effectiveness of this class of agents.
George Dangas, Valentin Fuster, John T. Fallon, Richard Hayes, Samin K. Sharma, Jonathan D. Marmur, Barry S. Coller, Lina Badimon, Juan J. Badimon, James H. Chesebro   +9 more
openaire   +3 more sources

Intracoronary tenecteplase versus abciximab as adjunctive treatment during primary percutaneous coronary intervention in patients with anterior myocardial infarction.

EuroIntervention, 2019
AIMS We sought to compare the effects of intracoronary administration of a fibrinolytic drug (tenecteplase) to those of a glycoprotein IIb/IIIa inhibitor (abciximab) in patients with ST-elevation myocardial infarction (STEMI) undergoing primary ...
Francisco J. Morales-Ponce, Francisco J. Lozano-Cid, P. Martínez-Romero, Pablo J. González-Pérez, J. Sánchez-Brotons, I. Diaz-Torres, J. C. Rodríguez-Yáñez, Pilar Caro-Mateo, A. Serrador-Frutos   +8 more
semanticscholar   +1 more source

Rationale for intracoronary administration of abciximab

Journal of Thrombosis and Thrombolysis, 2006
The present review aims to describe the pharmacological aspects as well as the available clinical data supporting the choice of intracoronary route of administration for abciximab, an antiplatelet drug used in patients with acute coronary syndromes undergoing percutaneous coronary interventions (PCI).
Romagnoli E., Burzotta F., Trani C., Biondi-Zoccai G. G. L., Giannico F., Crea F.   +5 more
openaire   +5 more sources

Half bolus dose of intravenous abciximab is safe and effective in the setting of acute stroke endovascular treatment

Journal of NeuroInterventional Surgery, 2018
Background A stent is often necessary for the treatment of stroke. In such cases,it is essential for the patient to have antiplatelet therapy.
F. Delgado, R. Oteros, E. Jiménez-Gómez, I. Bravo Rey, M. D. Bautista, R. Valverde Moyano   +5 more
semanticscholar   +1 more source